Glucosamine
An amino sugar the body already makes — sold in two very different forms
All articles checked for accuracy against the GB NHC Register and all sources have citations with verified links to their relevant studies.
Glucosamine is a familiar name on supplement labels — but the same molecule can come from shellfish or from a vegan fermentation process. Knowing the source matters for allergen labelling and dietary choice.
This article explains what glucosamine is, the two common commercial sources, how WellsparQ declares them on product cards, and what the research and regulatory bodies have actually concluded. It highlights why source and preparation matter more than marketing claims, and why WellsparQ states origin clearly on every label.
Ingredient Snapshot
- What it is
- An amino sugar (2‑amino‑2‑deoxy‑D‑glucose) used as a supplement ingredient.
- Where from
- Shellfish chitin or fermentation of plant feedstocks (e.g. corn).
- Known for
- A body‑made building block of connective‑tissue molecules; available as sulfate or hydrochloride salts.
- In WellsparQ
- FlexiDrive Collagen800 mg per serving
- JointEase Blend300 mg
- Workout Recovery Matrix0.5 g (500 mg)
- CapryGuard Complex8 mg
Glucosamine is one of the most familiar names in the joint-supplement aisle, and one of the most misunderstood. Two things about it deserve care from the outset. First, the evidence for the benefits people expect of it is genuinely mixed, and no health claim for it has been authorised. Second — and this is the practical point for anyone reading a WellsparQ label — glucosamine is sold in two chemically identical but very differently sourced forms: one made from shellfish, one made without. This page explains what glucosamine is, where it comes from, how WellsparQ declares it, and what the research has and has not settled.
What glucosamine is
Glucosamine is an amino sugar — a glucose molecule with an amino group in place of one hydroxyl (chemically 2-amino-2-deoxy-D-glucose) ¹. The body makes its own glucosamine, and it is a building block of larger molecules in cartilage and connective tissue, such as the glycosaminoglycans ¹. In supplements it usually appears as one of two salts: glucosamine sulfate or glucosamine hydrochloride (glucosamine HCl). WellsparQ uses the hydrochloride form.
The sourcing story — and why it matters on the label
This is the part to read slowly. Traditionally, commercial glucosamine is made by breaking down chitin, the tough material in the shells of crabs, prawns and other crustaceans ¹. Glucosamine produced this way is, unavoidably, a shellfish-derived ingredient and a declared allergen — and it is not suitable for vegans or vegetarians.
There is a second route. Glucosamine can also be produced by microbial fermentation — typically of a plant feedstock such as corn — giving the identical molecule with no shellfish involved. This fermentation-derived form is the one used for vegan glucosamine.
Both routes appear in the WellsparQ range, and the difference is declared honestly on each product.
| WellsparQ product | Declared glucosamine | Form | Source & suitability |
|---|---|---|---|
| FlexiDrive Collagen | 800 mg per serving | Glucosamine hydrochloride | Card: "from crustaceans", "Declared allergen source" — shellfish; not vegan |
| JointEase Blend | 300 mg | Glucosamine hydrochloride | Card: "from a vegan source" — "Glucosamine hydrochloride from a vegan process — no shellfish involved." |
| Workout Recovery Matrix | 0.5 g (500 mg) | Glucosamine hydrochloride | See product label for source |
| CapryGuard Complex | 8 mg | Glucosamine hydrochloride | A small, declared component |
Source: WellsparQ Supplements Database.
The contrast between the first two rows is the headline. FlexiDrive Collagen's glucosamine is from crustaceans — a recognised shellfish allergen, and not vegan. Anyone with a shellfish allergy, or following a plant-based or vegetarian diet, should treat FlexiDrive accordingly. JointEase Blend's glucosamine is the fermentation-derived vegan form — the card states plainly that there is no shellfish involved. Same molecule, two different origins, two different suitability answers. WellsparQ's habit is to say which is which on the pack rather than leave you guessing.
What the research has examined — honestly
Glucosamine has been studied mainly in the context of osteoarthritis (OA) of the knee and hip, and the results are, in a word, mixed. It is worth walking through the landmark evidence as evidence — who studied what, and what they found.
- The large US GAIT trial (Glucosamine/chondroitin Arthritis Intervention Trial), published in the New England Journal of Medicine in 2006, tested glucosamine hydrochloride, chondroitin, the two combined, a comparator drug and placebo in knee OA. Overall, glucosamine did not do significantly better than placebo for the primary pain outcome across the whole group ².
- A 2010 network meta-analysis in the BMJ pooled trials of glucosamine, chondroitin and their combination for hip and knee OA and concluded the effects on pain and joint-space narrowing were small and did not reach the threshold the authors set for clinical relevance ³.
- A Cochrane systematic review (2005) of glucosamine for OA found the picture depended heavily on which preparation and which trials were examined, with some (often industry-sponsored) studies of one particular sulfate product more favourable than others — highlighting how much the answer varies by brand, salt and trial quality ⁴.
Two honest points follow. Much of the more favourable data concerns a specific crystalline glucosamine sulfate preparation rather than the hydrochloride salt, and the two are not interchangeable in the evidence. And the trials disagree enough that no confident, generalisable benefit can be stated.
The claims and regulatory picture
Reflecting that mixed evidence, the European Food Safety Authority (EFSA) assessed proposed health claims for glucosamine and did not find the evidence sufficient: its opinions on glucosamine in relation to the maintenance of normal joints (EFSA Journal, 2012) and glucosamine hydrochloride in relation to reducing cartilage degeneration (EFSA Journal, 2009) were both unfavourable ⁵⁶. As a result, no joint or cartilage health claim is authorised for glucosamine under retained EU Regulation 1924/2006, and WellsparQ makes none.
A separate point of context: glucosamine's regulatory identity differs by country. In the United Kingdom and United States it is sold as a food supplement; in several other European countries a crystalline glucosamine sulfate is licensed as a prescription medicine for osteoarthritis ⁷. That medicine status abroad is a regulatory fact about a specific product in a specific country — it is not a benefit claim that transfers to a UK food supplement, and the two should never be conflated.
Where it fits your day
In the WellsparQ range, glucosamine is a declared component with its source stated plainly — crustacean-derived in FlexiDrive Collagen, vegan-fermentation in JointEase Blend. That transparency is the point. Rooted in nature, backed by research — and careful to let you read exactly what you are taking, and where it came from.
References
- National Center for Complementary and Integrative Health (NIH). Glucosamine and Chondroitin for Osteoarthritis. nccih.nih.gov (glucosamine as an amino sugar; component of cartilage; commercial sourcing from shellfish shells; salt forms). ↩ Back to text
- Clegg D.O., Reda D.J., Harris C.L. et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine 2006;354(8):795–808. PMID 16495392. ↩ Back to text
- Wandel S., Jüni P., Tendal B. et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010;341:c4675. PMID 20847017. ↩ Back to text
- Towheed T.E., Maxwell L., Anastassiades T.P. et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database of Systematic Reviews 2005;(2):CD002946. PMID 15846645. ↩ Back to text
- EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of a health claim related to glucosamine and maintenance of normal joints. EFSA Journal 2012;10(5):2691. doi:10.2903/j.efsa.2012.2691 (unfavourable). ↩ Back to text
- EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to glucosamine hydrochloride and reduction of the rate of cartilage degeneration (and related claims). EFSA Journal 2009;7(9):1264. doi:10.2903/j.efsa.2009.1264 (unfavourable). ↩ Back to text
- Regulatory status note — crystalline glucosamine sulfate is authorised as a prescription medicine for osteoarthritis in several EU member states, whereas glucosamine is marketed as a food supplement in the UK and US; see EFSA opinions ⁶ and NCCIH ¹ for the supplement context. (Country regulatory fact, not a benefit claim.) EFSA publications ↩ Back to text